Clinical Trial of 0.02% Polyhexamethylene Biguanide Versus Placebo in the Treatment of Microsporidial Keratoconjunctivitis

Diagnosis, clinical features and treatment outcome of microsporidial keratoconjunctivitis

“…Patients received either topical 0.02% polyhexamethylene biguanide ( n =88) or lubricants ( n =190) owing to a prospective randomised trial with placebo versus 0.02% polyhexamethylene biguanide, that was conducted during this period 13. Final visual acuity was ≥20/30 in 75.1% cases.…”

Clinical and demographic study of microsporidial keratoconjunctivitis in South India: a 3-year study (2013–2015)

“…Das et al 20 compared the time to heal and time to cure between PHMB and placebo in a randomised controlled trial and concluded that PHMB did not offer any advantage over placebo. In another randomised controlled trial by Das et al ,21 corneal debridement did not have a significant advantage in terms of resolution of the corneal lesions and final visual outcome in clinically diagnosed microsporidial keratoconjunctivitis.…”

Structural Characterization and Bacteriostatic and Cytotoxicity to 3T3 Cells Study of Oligobiguanidine (Polyhexamethylene Biguanidine Hydrochloride) and its 3-Glycidoxypropyltrimethoxysilane Derivatives

“…(14)(15)(16). Guanidines are also used as treatments of ophthalmological diseases against fungi and Acanthamoeba in infective keratitis, crystalline keratopathy, microsporidial keratoconjunctivitis (17)(18)(19). The antibacterial mechanism of PHMB was believed that it can disrupt the lipid cell membrane.…”